Product Data Sheet

RIP1 kinase inhibitor 9

Cat. No.: HY-163390 Molecular Formula: $C_{25}H_{21}N_3O_3$ Molecular Weight: 411.45

Target: RIP kinase; Necroptosis

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC $_{50}$ of 7.04 nM $^{[1]}$.
In Vitro	RIP1 kinase inhibitor 9 (10 nM, 4 h) effectively prevents the phosphorylation of both RIP1 and RIP3, hinders necrosome formation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	RIP1 kinase inhibitor 9 (5 mg/kg for p.o; daily for 7 days) suppresses inflammation in epileptic mice model $^{[1]}$. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jiang R, et al. Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy. Eur J Med Chem. 2024 Mar 9;269:116304.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA